Format

Send to

Choose Destination
Rev Med Inst Mex Seguro Soc. 2017 Mar-Apr;55(2):196-213.

[Use of recombinant Human Growth Hormone (rHGH)].

[Article in Spanish; Abstract available in Spanish from the publisher]

Author information

1
Servicio de Endocrinología, Instituto Nacional de Pediatría, Secretaría de Salud, Ciudad de México, México. raulcalzada@yahoo.com.

Abstract

in English, Spanish

Recombinant human growth hormone, synthesized in E.coli or mammalian cells cultures, is since 1985, a useful therapeutic resource to increase growth velocity and final height. In this paper are discussed the four phases (aims, security and efficacy, utility and efficiency) indispensables to define the start of treatment, as well as the absolute, relative and metabolic indications and the transitory and permanent conditions that contraindicate its use. It is commented the way to optimize the results (simple but indispensables indications for the physician, the patients and their family). Finally it is analyzed the results of treatment in patients with growth hormone deficiency, Turner syndrome, chronic renal failure, Prader-Willi syndrome, Noonan syndrome, SHOX deficiency, intrauterine growth retardation and idiopathic short stature.

KEYWORDS:

Hormones, hormone substitutes and hormone antagonists; Human growth hormone; Pituitary gonadotropins ; Recombinant proteins

PMID:
28296370
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center